2010 Press Releases

2009 Press Releases

2008 Press Releases

2007 Press Releases

2006 Press Releases

2005 Press Releases



2010 Press Releases

	August 09, 2010 Talecris Biotherapeutics and Grifols Receive FTC Request for Additional Information Regarding Proposed Merger
	July 14, 2010 Talecris Biotherapeutics Announces Premerger HSR Filing
	July 08, 2010 Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
	June 25, 2010 Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association
	June 18, 2010 Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
	June 15, 2010 Talecris Forms Partnership to Co-Promote Life-Saving Rabies Products
	June 07, 2010 Grifols to Acquire Talecris Biotherapeutics Creating a World Leading Provider of Life-Saving Plasma Protein Therapies
	June 03, 2010 Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
	April 28, 2010 Talecris Biotherapeutics Announces First Quarter 2010 Results
	April 20, 2010 Talecris Biotherapeutics Announces Results of Annual Stockholders' Meeting
	April 12, 2010 Gamunex(R) is the Preferred IGIV Therapy of Neurologists
	March 10, 2010 Talecris Biotherapeutics to Present at the Goldman Sachs Leveraged Finance Healthcare Conference
	February 23, 2010 Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2009 Results
	February 17, 2010 Talecris Biotherapeutics Receives Health Canada Approval for PROLASTIN®-C
	February 15, 2010 Talecris Biotherapeutics Donates Vital Medical Treatment and Supplies to Haitian Relief Efforts
	February 10, 2010 Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2009 Financial Results
	February 10, 2010 Talecris Biotherapeutics Announces Record Date for 2010 Annual Meeting of Shareholders
	February 05, 2010 Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Alpha1-Proteinase Inhibitor to Treat Alpha1-Antitrypsin Deficiency
	January 07, 2010 Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations

2009 Press Releases

	December 17, 2009 Dean Mitchell Appointed to Talecris Board of Directors
	November 10, 2009 Talecris Biotherapeutics Announces Third Quarter 2009 Results
	October 30, 2009 Talecris Biotherapeutics to Report Third Quarter 2009 Financial Results
	October 21, 2009 Talecris Biotherapeutics Receives FDA Approval for PROLASTIN(R)-C
	October 16, 2009 Talecris Biotherapeutics Announces Pricing of $600 Million Senior Notes due 2016
	October 15, 2009 The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc
	October 13, 2009 Talecris Biotherapeutics Announces Private Offering of $550 Million Senior Notes due 2016
	October 07, 2009 Talecris Announces Closing of Initial Public Offering and Exercise of Over - Allotment Option
	September 30, 2009 Talecris Biotherapeutics Prices Initial Public Offering of Common Stock at $19.00 Per Share
	September 15, 2009 Talecris Commences Initial Public Offering of Common Stock
	June 09, 2009 Talecris Biotherapeutics Receives Orphan Drug Designation for Plasmin (Human) to Treat Acute Peripheral Arterial Occlusion
	June 04, 2009 Alpha-1 Foundation Announces the Million Dollar Match Program Made Possible by a Talecris Biotherapeutics Grant
	May 28, 2009 Talecris Responds to U.S. Federal Trade Commission Filing of Complaint to Challenge Proposed CSL Transaction
	May 18, 2009 Talecris Presents New Data from Phase III Studies of a More Concentrated Formulation of Prolastin® to Treat AAT Deficiency
	April 23, 2009 New Publication of Landmark Study Demonstrates Gamunex® Improves Health-Related Quality of Life in Patients with CIDP
	February 09, 2009 Talecris Biotherapeutics, Inc. Names its 2009 Talents Grant Recipients
	February 05, 2009 Thrombate III® Approved for Room Temperature Storage

2008 Press Releases

	November 18, 2008 The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
	October 15, 2008 Talecris Biotherapeutics Helps Patients Receive Gamunex® During Lapses in Private Insurance Coverage
	October 14, 2008 Health Canada Grants Approval to Talecris Biotherapeutics for Gamunex as a Treatment for Neurological Disorder CIDP in Canada
	September 23, 2008 Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response in Some Patients with CIDP
	September 23, 2008 Sub-Analysis of Phase III Suggests Long-Term Therapy May Improve Physical and Social Functioning In CIDP Patients
	September 18, 2008 Jeffrey Modell Foundation and Talecris Biotherapeutics, Inc. Expand Diagnostic Services for Primary Immunodeficiencies at Children's Hospital Boston
	September 15, 2008 FDA Grants Approval to Talecris Biotherapeutics for Gamunex® as a Treatment for Neurological Disorder CIDP in the United States
	September 12, 2008 Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Children's Medical Center
	August 20, 2008 Frankfurt University Hospital opens Hessen’s First Centre for Primary Immunodeficiencies
	August 12, 2008 Talecris Enters into Definitive Merger Agreement with CSL
	July 24, 2008 Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Form of Alpha-1 Antitrypsin (AAT) From the European Commission
	June 16, 2008 Talecris Biotherapeutics, Inc. Provides Business Update
	May 22, 2008 Talecris Biotherapeutics Awarded MedAssets Supply Chain Systems' Platinum Vendor Designation
	May 14, 2008 Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
	May 14, 2008 Talecris Announces 2008 Application Cycle for Talents Research Grants, Presents 2007 Grant Awardees
	May 08, 2008 FDA Grants Priority Review of Gamunex® as a Treatment for Neurological Disorder CIDP
	April 28, 2008 Talecris Partners with Catalent Pharma Solutions for European Contract Manufacturing and Product Testing
	April 07, 2008 Die vom global agierenden Biotechnologieunternehmen Talecris Biotherapeutics, Inc. finanzierte „ICE-Studie“ ist die bislang größte veröffentlichte
	March 31, 2008 Talecris Biotherapeutics Awarded Manufacturing Contract to Supply Canada with Biological Therapies for the 20th Consecutive Year
	March 03, 2008 Jeffrey Modell Foundation and Talecris Biotherapeutics Expand Diagnostic Services for Primary Immunodeficiencies at Lucile Packard Children's Hospital at Stanford
	February 21, 2008 Talecris Biotherapeutics Celebrates 20th Anniversary of Launch of Prolastin®
	February 13, 2008 Talecris Plasma Resources Reports Solid Progress Developing Plasma Collection Capabilities
	February 07, 2008 Positive Results from Phase III Trial of Gamunex® in Patients with CIDP
	January 31, 2008 Prolastin.com Receives Gold Award from Association of Marketing and Communication Professionals
	January 17, 2008 Precision Pharma Services Merges Into Talecris Biotherapeutics

2007 Press Releases

	November 12, 2007 www.Prolastin.com Named Best Biotechnology Web Site of 2007
	October 02, 2007 Talecris Announces New Hypermune™ Product Safety Advances
	September 18, 2007 Study Demonstrates Aerosolized Prolastin® Using Unique Nebulizer Results in High Levels of Drug Deposited in Peripheral Regions of Lungs
	September 16, 2007 Talecris Biotherapeutics awards Winners of the 4th European ALTA Fellowship Program
	August 27, 2007 Talecris-Sponsored Scientific Symposium Examines Advances in Use of Intravenous Immune Globulin for Neurological Disorders
	August 14, 2007 Gamunex® is Now Latex-Free
	August 08, 2007 Talecris Biotherapeutics Debuts CIDPinfo.com for Neurologists and Healthcare Providers
	July 11, 2007 New Information on the Potential of Plasmin Shared at ISTH Congress
	June 12, 2007 Talecris Plasma Resources Supplements Its Collection: Acquisition Adds New Centers
	May 08, 2007 Talecris Biotherapeutics’ Talents Program Accepting Applications for 2007 Research Grant Awards
	May 03, 2007 Talecris Provides Educational Grant to Support World Federation of Hemophilia’s Global Laboratory Science Program
	March 20, 2007 Talecris Initiates Clinical Development Program Evaluating Plasmin for Dissolving Blood Clots and Restoring Blood Flow in Legs
	February 23, 2007 Gamunex® is the Preferred Liquid IGIV Therapy Among Allergists and Immunologists Surveyed
	February 15, 2007 Talecris’ Product Integrity Enhanced With Environmentally-friendly Shipping Containers
	February 13, 2007 Talecris Plasma Resources Opens First New Center in Champaign, Illinois
	February 01, 2007 Talecris Biotherapeutics supports projects in the field of Alpha-1-Antitrypsin Deficiency with eALTA fellowships
	January 04, 2007 Talecris Names Inaugural Talents Grant Recipients

2006 Press Releases

	December 01, 2006 Talecris Continues Global Expansion into Europe
	November 20, 2006 Talecris Biotherapeutics Completes Acquisition of Plasma Collection Centers
	November 03, 2006 Talecris Biotherapeutics Named a "Fast 50" Company
	October 28, 2006 IDF Center of Excellence Dedicated at Duke University
	October 26, 2006 New Pediatrician Education Program Launched to Increase Awareness and Improve Diagnosis of Immunodeficiencies in Children
	October 09, 2006 Immune Deficiency Foundation Launches Free Electronic Newsletter
	October 05, 2006 Talecris Biotherapeutics Celebrates 25 Years of Life-Saving Treatment for People with Primary Immune Deficiency
	September 05, 2006 Extensive Post-License Data Reaffirm Clinical Safety Profile of Prolastin®
	September 05, 2006 Pathogen Safety Reconfirmed for Prolastin®
	September 05, 2006 Talecris Biotherapeutics Awards Third Annual European ALTA Fellowships
	August 29, 2006 Bausch & Lomb Licenses rPlasmin from Talecris Biotherapeutics for Ophthalmic Use
	June 28, 2006 Talecris Biotherapeutics Announces Start of Licensing Clinical Trials for Alpha-1 Antitrypsin Using Modified Manufacturing Process
	May 22, 2006 Landmark Alpha-1 Historical Medical Literature Available from Talecris Biotherapeutics
	May 03, 2006 Talecris Biotherapeutics Launches Talents: Talecris New Trials Support Program
	April 03, 2006 Talecris Biotherapeutics Announces Global Expansion
	January 25, 2006 Grant from Talecris Biotherapeutics Will Support Primary Immunodeficiency Diagnosis and Patient Access to Care

2005 Press Releases

	November 09, 2005 Talecris Biotherapeutics' Manufacturing Processes Safeguard Against Avian Bird Flu
	November 04, 2005 Talecris Biotherapeutics Showcases Its Clayton Facility to State and Local Dignitaries
	October 27, 2005 Talecris Biotherapeutics Strengthens its Executive Leadership Team
	October 13, 2005 Talecris Celebrates the Second Anniversary of Gamunex®
	October 13, 2005 Talecris Biotherapeutics Initiates Voluntary Recall of Plasmanate®
	October 04, 2005 Talecris Biotherapeutics Receives QSEAL Certification from PPTA
	September 27, 2005 Talecris Biotherapeutics Awards Second Annual ALTA Fellowships
	August 18, 2005 Talecris Announces Extended Room Temperature Storage for Gamunex®
	August 09, 2005 Talecris Biotherapeutics and BBI Sign Development Agreement for Alpha-1 Antitrypsin Test
	July 07, 2005 Labeling for Gamunex® now Includes Assurances of Removal of Pathogenic Prions During Manufacture
	June 16, 2005 Talecris Biotherapeutics Reaffirms Commitment to Set Industry Standard for Product Integrity
	May 26, 2005 Talecris Biotherapeutics Becomes First Plasma Fractionator to Perform In-house HBV Screening Using FDA-Licensed Protocol
	April 28, 2005 An Evening Symposium held during the European Respiratory Society Annual Congress 2005, Copenhagen
	April 01, 2005 Announcing the Launch of Talecris Biotherapeutics: Combining a Proud History of Patient Care with a Bold New Vision
	January 07, 2005 Bausch & Lomb To License Plasmin from Bayer HealthCare for Ophthalmic Use